Does Sivextro Work Against MRSA Skin Infections?
Sivextro (tedizolid phosphate) is FDA-approved for treating acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).[1][2] Clinical trials showed it clears MRSA infections as effectively as linezolid, the standard comparator, with 92-98% clinical success rates at end-of-therapy for MRSA-positive ABSSSI cases.[3]
In the ESTABLISH-1 trial (1,066 patients), tedizolid 200 mg once daily for 6 days achieved 97.6% success against MRSA ABSSSI, versus 93.2% for linezolid 600 mg twice daily for 10 days.[4] ESTABLISH-2 (666 patients) reported 92.2% success for tedizolid versus 88.6% for linezolid.[4] These results held across microbiologically confirmed MRSA subsets, with microbiologic eradication rates of 90-94%.[3][4]
How Does Sivextro Target MRSA?
Tedizolid inhibits bacterial protein synthesis by binding the 50S ribosomal subunit, with strong activity against MRSA strains, including those resistant to linezolid or with reduced vancomycin susceptibility.[5] Its MIC90 (minimum concentration inhibiting 90% of MRSA isolates) is 0.5 μg/mL, lower than linezolid's 4 μg/mL, indicating greater potency.[6] Once-daily dosing and shorter 6-day course improve patient adherence over linezolid's regimen.[2]
Compared to Vancomycin or Daptomycin for MRSA Skin Infections?
Tedizolid matches linezolid's efficacy but offers advantages over vancomycin (IV-only, monitoring required) and daptomycin (higher cost, muscle toxicity risk).[7] In MRSA ABSSSI, tedizolid had fewer adverse events (15% vs. 25% for linezolid) and less gastrointestinal upset.[4] Real-world studies confirm similar MRSA cure rates (85-95%) with oral/IV flexibility.[8]
| Treatment | MRSA Success Rate (ABSSSI) | Dosing | Key Drawback |
|-----------|-----------------------------|--------|--------------|
| Sivextro | 92-98% [3][4] | 200 mg oral/IV daily x6 days | Higher cost |
| Linezolid | 88-93% [4] | 600 mg oral/IV BID x10 days | Myelosuppression risk |
| Vancomycin | 85-90% [7] | IV BID, trough monitoring | Infusion reactions |
What About Treatment Failures or Resistant Strains?
Sivextro succeeds in most susceptible MRSA cases but fails against tedizolid-resistant mutants (rare, <1% prevalence).[9] It's not indicated for vancomycin-intermediate or -resistant MRSA (VIM-R/VR-MRSA) without susceptibility testing.[2] Local resistance patterns matter—check CLSI breakpoints (≤0.5 μg/mL susceptible).[10]
Common Side Effects in MRSA Patients
Nausea (4-8%), headache (6%), and diarrhea (3-5%) occur most often; serious risks like Clostridium difficile infection or serotonin syndrome are low (≤1%).[2][11] Shorter course reduces myelosuppression versus linezolid.[4]
Availability, Cost, and Patent Status
Sivextro costs $3,000-$4,000 for a 6-day course (US wholesale), higher than generics but competitive with branded linezolid.[12] Merck holds U.S. patents until 2036, blocking generics; no biosimilars exist.[13] DrugPatentWatch.com
Sources
[1]: FDA Label - Sivextro (2014) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
[2]: Sivextro Prescribing Information (Merck, 2023)
[3]: Prokocimer et al., Clin Infect Dis (2013)
[4]: Prokocimer et al., Antimicrob Agents Chemother (2014)
[5]: Biedenbach et al., Diagn Microbiol Infect Dis (2010)
[6]: CLSI M100 (2023)
[7]: Lipsky et al., Clin Infect Dis (2005)
[8]: Vardakas et al., J Antimicrob Chemother (2019)
[9]: CDC AR Lab Network (2022)
[10]: CLSI Breakpoints
[11]: FDA Adverse Event Reporting System
[12]: Red Book (2024)
[13]: DrugPatentWatch.com - Sivextro